clinical trial · NCT07200986
Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects
Celltrion·phase1·active not recruiting·n = 218
Healthy ParticipantsIxekizumab
brief summary
This study is designed to demonstrate PK similarity of the proposed biosimilar test product CT-P52 and the reference product, US-licensed Taltz.
started
Sep 17, 2025
primary completion
Mar 31, 2026
completion
Mar 31, 2026
last updated
Dec 31, 2025
official title
A Phase 1, Randomized, Double-blind, Two-arm, Parallel-Group, Single-dose Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol